132 related articles for article (PubMed ID: 11418153)
1. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer.
Tartour E; Mosseri V; Jouffroy T; Deneux L; Jaulerry C; Brunin F; Fridman WH; Rodriguez J
Lancet; 2001 Apr; 357(9264):1263-4. PubMed ID: 11418153
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.
El Houda Agueznay N; Badoual C; Hans S; Gey A; Vingert B; Peyrard S; Quintin-Colonna F; Ravel P; Bruneval P; Roncelin S; Lelongt B; Bertoglio J; Fridman WH; Brasnu D; Tartour E
Clin Exp Immunol; 2007 Oct; 150(1):114-23. PubMed ID: 17680822
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.
Wang LS; Chow KC; Li WY; Liu CC; Wu YC; Huang MH
Clin Cancer Res; 2000 Apr; 6(4):1445-51. PubMed ID: 10778976
[TBL] [Abstract][Full Text] [Related]
4. The soluble interleukin-2 receptor--a marker for squamous cell carcinoma of the upper aerodigestive tract.
Gottschlich S; Görögh T; Lippert BM; Niemann AM; Folz BJ; Werner JA
Anticancer Res; 1997; 17(4B):2921-2. PubMed ID: 9329564
[TBL] [Abstract][Full Text] [Related]
5. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
[TBL] [Abstract][Full Text] [Related]
6. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study.
Tartour E; Deneux L; Mosseri V; Jaulerry C; Brunin F; Point D; Validire P; Dubray B; Fridman WH; Rodriguez J
Cancer; 1997 Apr; 79(7):1401-8. PubMed ID: 9083163
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte ratio: Prognostic indicator for head and neck squamous cell carcinoma.
Rosculet N; Zhou XC; Ha P; Tang M; Levine MA; Neuner G; Califano J
Head Neck; 2017 Apr; 39(4):662-667. PubMed ID: 28075517
[TBL] [Abstract][Full Text] [Related]
8. [Neutrophil to lymphocyte ratio in peripheral blood: a novel independent prognostic factor in patients with head and neck squamous cell carcinoma].
Wu F; Wu LL; Zhu LX
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):29-32. PubMed ID: 28104030
[No Abstract] [Full Text] [Related]
9. Alteration of serum lipid profile and its prognostic value in head and neck squamous cell carcinoma.
Li G; Da M; Zhang W; Wu H; Ye J; Chen J; Ma L; Gu N; Wu Y; Song X
J Oral Pathol Med; 2016 Mar; 45(3):167-72. PubMed ID: 26189546
[TBL] [Abstract][Full Text] [Related]
10. Serum prognostic biomarkers in head and neck cancer patients.
Lin HS; Siddiq F; Talwar HS; Chen W; Voichita C; Draghici S; Jeyapalan G; Chatterjee M; Fribley A; Yoo GH; Sethi S; Kim H; Sukari A; Folbe AJ; Tainsky MA
Laryngoscope; 2014 Aug; 124(8):1819-26. PubMed ID: 24347532
[TBL] [Abstract][Full Text] [Related]
11. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
[TBL] [Abstract][Full Text] [Related]
12. Study of cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma.
Céruse P; Rabilloud M; Charrié A; Dubreuil C; Disant F
Ann Otol Rhinol Laryngol; 2005 Oct; 114(10):768-76. PubMed ID: 16285267
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma.
Park MJ; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2018 Mar; 92():69-76. PubMed ID: 29428866
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of soluble interleukin-2 receptor in patients with malignant brain tumors.
Yoshida S; Morii K
J Surg Oncol; 2000 Oct; 75(2):131-5. PubMed ID: 11064393
[TBL] [Abstract][Full Text] [Related]
15. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.
Kuropkat C; Lippert BM; Werner JA
Oncology; 2002; 63(3):280-5. PubMed ID: 12381908
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma.
Druzgal CH; Chen Z; Yeh NT; Thomas GR; Ondrey FG; Duffey DC; Vilela RJ; Ende K; McCullagh L; Rudy SF; Muir C; Herscher LL; Morris JC; Albert PS; Van Waes C
Head Neck; 2005 Sep; 27(9):771-84. PubMed ID: 15920746
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of insulin resistance on disease-free survival in head and neck squamous cell carcinomas: Preliminary results.
Avilés-Jurado FX; Flores JC; Gumà J; Ceperuelo-Mallafré V; Casanova-Marqués R; Gómez D; Vendrell JJ; León X; Vilaseca I; Terra X
Head Neck; 2017 Dec; 39(12):2501-2511. PubMed ID: 28963801
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma.
Pardo L; Valero C; López M; García J; Camacho M; Quer M; León X
Auris Nasus Larynx; 2017 Jun; 44(3):313-318. PubMed ID: 27401121
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of laminin gamma2 fragments in patients with head and neck squamous cell carcinoma.
Kuratomi Y; Sato S; Monji M; Shimazu R; Tanaka G; Yokogawa K; Inoue A; Inokuchi A; Katayama M
Head Neck; 2008 Aug; 30(8):1058-63. PubMed ID: 18446818
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of clinical and
Cho JK; Hyun SH; Choi JY; Choi N; Kim MJ; Lee SH; Baek KH; Jeong HS
J Surg Oncol; 2016 Dec; 114(7):888-894. PubMed ID: 27546387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
